ArticleRheumatology international2026
Calprotectin and serum amyloid A for disease activity assessment in giant cell arteritis and polymyalgia rheumatica: results from a prospective single-centre cohort study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Monitoring disease activity in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) is commonly based on C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Both markers are unreliable during interleukin-6 receptor inhibitor (IL-6Ri) therapy. We evaluated calprotectin (CALPR) and serum amyloid A (SAA) as alternative biomarkers. In a prospective single-centre cohort, we obtained 576 serial measurements from 98 patients with GCA (n = 81) or PMR (n = 17) between 2019 and 2022. Disease activity was classified as “active” or “remission” according to current EULAR recommendations. CRP, ESR, CALPR, and SAA were analysed and compared between patients treated with and without tocilizumab (TCZ). Univariate mixed-effects logistic regression models were fitted for the marker and used for receiver operating characteristic (ROC) analyses; multivariable mixed-effects models were used to adjust for clinical covariates. Active disease was present at 131 of 576 visits (22.7%), and 140 visits (24.3%) occurred under tocilizumab (TCZ) treatment. In patients without TCZ, ROC analysis showed the best discrimination for CRP (AUC 0.76, 95% CI 0.69–0.83), followed by SAA (0.74, 0.67–0.81), ESR (0.70, 0.63–0.78), and calprotectin (CALPR; 0.66, 0.59–0.73). Under TCZ treatment, SAA achieved the highest AUC (0.72, 95% CI 0.51–0.90), outperforming CRP (0.58, 0.42–0.77), CALPR (0.56, 0.32–0.74), and ESR (0.48, 0.30–0.67). In multivariable mixed-effects models, CRP, ESR, and SAA remained significantly associated with active disease in patients without TCZ, whereas none of the markers distinguished active disease from remission under TCZ treatment. SAA outperformed conventional markers in detecting active disease during IL-6Ri therapy in univariate analysis, but no biomarker retained significance after adjustment. These findings underscore the limitations of current laboratory monitoring in GCA and PMR under IL-6 inhibition and highlight the need for further evaluation of IL-6–independent biomarkers.
Indexed as
Identifiers
41779206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.